Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Impact of germline and somatic TP53 mutations on allogeneic HSCT outcomes in hematologic malignancies

Xingyu Cao, Yang Zhang, Lili Yuan, Yue Lu, Jian-Ping Zhang, Zhijie Wei, Deyan Liu, Min Xiong, Yanli Zhao, Jiarui Zhou, Ruijuan Sun, Mengyuan Niu, Fangmin Pan, Jing Long, Peihua Lu

Blood (2025) 146 (Supplement 1): 7786.

https://doi.org/10.1182/blood-2025-7786

Published: 2025

Journal Articles

Allogeneic hematopoietic stem cell transplantation in sil::TAL1-positive T-ALL: Prognostic impact of pre-transplant remission and molecular status

Xiao-hong Liu, Jing Long, Jiarui Zhou, Min Xiong, Xingyu Cao, Jian-Ping Zhang, Yue Lu, Zhijie Wei, Yanli Zhao, Ruijuan Sun, Fangmin Pan, Peihua Lu, Deyan Liu

Blood (2025) 146 (Supplement 1): 2502.

https://doi.org/10.1182/blood-2025-2502

Published: 2025

Journal Articles

Optimizing letermovir timing: Day +5 to +8 post haplo-HSCT minimizes EBV dnaemia without compromising CMV prophylaxis

Xingyu Cao, Yue Lu, Jian-Ping Zhang, Zhijie Wei, Deyan Liu, Min Xiong, Yanli Zhao, Jiarui Zhou, Ruijuan Sun, Mengyuan Niu, Fangmin Pan, Jing Long, Peihua Lu

Blood (2025) 146 (Supplement 1): 2500.

https://doi.org/10.1182/blood-2025-2500

Published: 2025

Journal Articles

The impact of HLA loss of heterozygosity on outcome after haploidentical hematopoietic stem cell transplantation in hematological malignancies

Xingyu Cao, Jian-ling Wang, Yanli Zhao, Min Xiong, Yue Lu, Ruijuan Sun, Jian-Ping Zhang, Deyan Liu, Jiarui Zhou, Zhijie Wei, Peihua Lu

Blood (2025) 146 (Supplement 1): 2498.

https://doi.org/10.1182/blood-2025-2498

Published: 2025

Journal Articles

No reduction in gvhd risk for aplastic anemia patients to combined third-party unrelated cord blood in haploidentical hematopoietic stem cells transplantation

Wei Zhao, Xingyu Cao, Yue Lu, Jian-Ping Zhang, Zhijie Wei, Deyan Liu, Min Xiong, Jiarui Zhou, Ruijuan Sun, Jing Long, Peihua Lu, Yanli Zhao

Blood (2025) 146 (Supplement 1): 2495.

https://doi.org/10.1182/blood-2025-2495

Published: 2025

Journal Articles

Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes

Yanli Zhao, Yue Lu, Deyan Liu, Jian-Ping Zhang, Zhijie Wei, Xingyu Cao, Ruijuan Sun, Jiarui Zhou, Min Xiong, Jing Long, Tong Wang, Peihua Lu

Blood (2025) 146 (Supplement 1): 2493.

https://doi.org/10.1182/blood-2025-2493

Published: 2025

Journal Articles

Clinical efficacy of allogeneic hematopoietic stem cell transplantation in infant acute leukemia

Ruijuan Sun, Min Xiong, Zhijie Wei, Deyan Liu, Jian-Ping Zhang, Jiarui Zhou, Xingyu Cao, Yue Lu, Yanli Zhao, Peihua Lu

Blood (2025) 146 (Supplement 1): 6053.

https://doi.org/10.1182/blood-2025-6053

Published: 2025

Journal Articles

CD3⁺cell dose is an independent risk factor for grade II–IV aGVHD following cord blood transplantation in children with aplastic anemia

Jian-Ping Zhang, Li Nannan, Min Xiong, Jing Long, Xingyu Cao, Yue Lu, Zhijie Wei, Deyan Liu, Ruijuan Sun, Jiarui Zhou, Yanli Zhao, Jun-bao He, Peihua Lu

Blood (2025) 146 (Supplement 1): 7752.

https://doi.org/10.1182/blood-2025-7752

Published: 2025

Journal Articles

Single-center retrospective analysis of maribavir in the treatment of refractory and drug-intolerant cytomegalovirus viremia and cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation

Wei Ma, Xingyu Cao, Jiarui Zhou, Jian-Ping Zhang, Yue Lu, Ruijuan Sun, Zhijie Wei, Deyan Liu, Yanli Zhao, Min Xiong, Peihua Lu

Blood (2025) 146 (Supplement 1): 6059.

https://doi.org/10.1182/blood-2025-6059

Published: 2025

Journal Articles

Allo-HSCT mitigates the prognostic differences between bZIP and non-bZIP CEBPA mutations in AML: A long-term follow-up study of lu daopei hospital

Yanli Zhao, Yue Lu, Deyan Liu, Jian-Ping Zhang, Zhijie Wei, Xingyu Cao, Ruijuan Sun, Min Xiong, Jiarui Zhou, Jing Long, Tong Wang, Hongxing Liu, Peihua Lu

Blood (2025) 146 (Supplement 1): 6049.

https://doi.org/10.1182/blood-2025-6049

Published: 2025

Journal Articles

Enhanced long-term outcomes with third-party unrelated cord blood co-infusion in a 122-patients cohort undergoing second allo-HSCT for AML in remission

Wei Zhao, Xingyu Cao, Yue Lu, Jian-Ping Zhang, Zhijie Wei, Deyan Liu, Min Xiong, Jiarui Zhou, Ruijuan Sun, Yanli Zhao, Peihua Lu

Blood (2025) 146 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2025-4262

Published: 2025

Journal Articles

Long-term outcomes of allo-HSCT in SET::CAN-positive Hematological Malignancies: A 12-year single-center Study of 36 patients

Xiaomei Liu, Jing Long, Deyan Liu, Jian-Ping Zhang, Yue Lu, Zhijie Wei, Yanli Zhao, Xingyu Cao, Min Xiong, Jiarui Zhou, Ruijuan Sun, Fangmin Pan, Mengyuan Niu, Peihua Lu

Blood (2025) 146 (Supplement 1): 2482.

https://doi.org/10.1182/blood-2025-2482

Published: 2025

Journal Articles

A Long-Term Follow-up Retrospective Study of the Clinical Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation for Early T-Precursor Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Xingyu Cao, Yue Lu, Jian-Ping Zhang, Deyan Liu, Zhijie Wei, Yanli Zhao, Jiarui Zhou, Min Xiong, Ruijuan Sun, Jing Long, Peihua Lu

Blood (2024) 144 (Supplement 1): 4934.

https://doi.org/10.1182/blood-2024-204579

Published: 2024

Journal Articles

Comparable OS and Gffs of ATLG Vs. Ratg for Gvhd Prophylaxis in Pediatric AA Patients Undergoing Transplantation

Li Nannan, Yue Lu, Deyan Liu, Min Xiong, Yanli Zhao, Ruijuan Sun, Zhijie Wei, Xingyu Cao, Jiarui Zhou, Jianping Zhang, Peihua Lu

Blood (2024) 144 (Supplement 1): 3537.

https://doi.org/10.1182/blood-2024-209027

Published: 2024

Journal Articles

Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for 532 Patients with KMT2A-Rearranged Acute Leukemia

Ruijuan Sun, Yue Lu, Jian-Ping Zhang, Jiarui Zhou, Deyan Liu, Yanli Zhao, Zhijie Wei, Min Xiong, Xingyu Cao, Peihua Lu

Blood (2024) 144 (Supplement 1): 3546.

https://doi.org/10.1182/blood-2024-206907

Published: 2024

Journal Articles

CD7 CAR-T Therapy Followed By a Second Transplant for T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients Who Relapsed after a Prior Transplant

Xingyu Cao, Jianping Zhang, Yue Lu, Yanli Zhao, Deyan Liu, Min Xiong, Zhijie Wei, Jiarui Zhou, Xian Zhang, Junfang Yang, Hongxing Liu, Peihua Lu

Blood (2023) 142 (Supplement 1): 2155.

https://doi.org/10.1182/blood-2023-186030

Published: 2023

Journal Articles

A Parallel Comparison of the Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for Refractory and Relapsed T-ALL/Lbl Patients Who Achieved Complete Remission with CD7 CAR-T Versus Patients Who Achieved First Complete Remission with Chemotherapy before Transplantation

Xingyu Cao, Jianping Zhang, Yue Lu, Yanli Zhao, Deyan Liu, Min Xiong, Ruijuan Sun, Zhijie Wei, Jiarui Zhou, Xian Zhang, Junfang Yang, Hongxing Liu, Sr., Peihua Lu

Blood (2023) 142 (Supplement 1): 3611.

https://doi.org/10.1182/blood-2023-185696

Published: 2023

Journal Articles

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

Xing-yu Cao, Jian-Ping Zhang, Yan-Li Zhao, Min Xiong, Jiarui Zhou, Yue Lu, Ruijuan Sun, Zhijie Wei, Deyan Liu, Xian Zhang, Junfang Yang, Peihua Lu

Blood (2022) 140 (Supplement 1): 4802–4803.

https://doi.org/10.1182/blood-2022-166993

Published: 2022

Journal Articles

Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant

Jianping Zhang, Junfang Yang, Xian Zhang, MD, Jingjing Li, Xingyu Cao, Yanli Zhao, Zhijie Wei, Deyan Liu, Min Xiong, Yue Lu, Jiarui Zhou, Ruijuan Sun, Peihua Lu, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136014

Published: 2020

Journal Articles

To Explore the Effect of Haploidentical Transplantation in the Treatment of Pediatric T-ALL with Sil-TAL1 Fusion Gene Positive and Analysis of Prognostic Factors

Huili Zhu, MD, Peihua Lu, MD, Deyan Liu, Yanli Zhao, Jiarui Zhou, Jianping Zhang, Xingyu Cao, Yue Lu, Zhijie Wei

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139583

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Impact of germline and somatic TP53 mutations on allogeneic HSCT outcomes in hematologic malignancies

Allogeneic hematopoietic stem cell transplantation in sil::TAL1-positive T-ALL: Prognostic impact of pre-transplant remission and molecular status

Optimizing letermovir timing: Day +5 to +8 post haplo-HSCT minimizes EBV dnaemia without compromising CMV prophylaxis

The impact of HLA loss of heterozygosity on outcome after haploidentical hematopoietic stem cell transplantation in hematological malignancies

No reduction in gvhd risk for aplastic anemia patients to combined third-party unrelated cord blood in haploidentical hematopoietic stem cells transplantation

Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes

Clinical efficacy of allogeneic hematopoietic stem cell transplantation in infant acute leukemia

CD3⁺cell dose is an independent risk factor for grade II–IV aGVHD following cord blood transplantation in children with aplastic anemia

Single-center retrospective analysis of maribavir in the treatment of refractory and drug-intolerant cytomegalovirus viremia and cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation

Allo-HSCT mitigates the prognostic differences between bZIP and non-bZIP CEBPA mutations in AML: A long-term follow-up study of lu daopei hospital

Enhanced long-term outcomes with third-party unrelated cord blood co-infusion in a 122-patients cohort undergoing second allo-HSCT for AML in remission

Long-term outcomes of allo-HSCT in SET::CAN-positive Hematological Malignancies: A 12-year single-center Study of 36 patients

A Long-Term Follow-up Retrospective Study of the Clinical Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation for Early T-Precursor Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Comparable OS and Gffs of ATLG Vs. Ratg for Gvhd Prophylaxis in Pediatric AA Patients Undergoing Transplantation

Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for 532 Patients with KMT2A-Rearranged Acute Leukemia

CD7 CAR-T Therapy Followed By a Second Transplant for T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients Who Relapsed after a Prior Transplant

A Parallel Comparison of the Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for Refractory and Relapsed T-ALL/Lbl Patients Who Achieved Complete Remission with CD7 CAR-T Versus Patients Who Achieved First Complete Remission with Chemotherapy before Transplantation

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant

To Explore the Effect of Haploidentical Transplantation in the Treatment of Pediatric T-ALL with Sil-TAL1 Fusion Gene Positive and Analysis of Prognostic Factors

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only